| Title |
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials
|
|---|---|
| Published in |
Diabetologia, August 2012
|
| DOI | 10.1007/s00125-012-2653-7 |
| Pubmed ID | |
| Authors |
R. J. Stevens, R. Ali, C. R. Bankhead, M. A. Bethel, B. J. Cairns, R. P. Camisasca, F. L. Crowe, A. J. Farmer, S. Harrison, J. A. Hirst, P. Home, S. E. Kahn, J. H. McLellan, R. Perera, A. Plüddemann, A. Ramachandran, N. W. Roberts, P. W. Rose, A. Schweizer, G. Viberti, R. R. Holman |
| Abstract |
Observational studies suggest that metformin may reduce cancer risk by approximately one-third. We examined cancer outcomes and all-cause mortality in published randomised controlled trials (RCTs). |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 5 | 42% |
| Spain | 1 | 8% |
| Unknown | 6 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 83% |
| Practitioners (doctors, other healthcare professionals) | 2 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 106 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 3% |
| Brazil | 1 | <1% |
| France | 1 | <1% |
| South Africa | 1 | <1% |
| Lithuania | 1 | <1% |
| Unknown | 99 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 17 | 16% |
| Researcher | 16 | 15% |
| Student > Ph. D. Student | 14 | 13% |
| Other | 10 | 9% |
| Professor | 9 | 8% |
| Other | 23 | 22% |
| Unknown | 17 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 55 | 52% |
| Agricultural and Biological Sciences | 7 | 7% |
| Social Sciences | 4 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Other | 11 | 10% |
| Unknown | 22 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2023.
All research outputs
#1,324,524
of 25,008,338 outputs
Outputs from Diabetologia
#723
of 5,329 outputs
Outputs of similar age
#7,409
of 175,303 outputs
Outputs of similar age from Diabetologia
#5
of 66 outputs
Altmetric has tracked 25,008,338 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,329 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.5. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 175,303 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 66 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.